CD274 and colon adenocarcinoma: Results from Sow et al. (2019) have corroborated this pattern by demonstrating that the combination of an anti-PD-L1 antibody with a TβRI kinase inhibitor lead to increased survival in the highly immunogenic mouse MC38 colon adenocarcinoma model.